Purpose: To investigate the impact of three different macular carotenoid formulations on macular pigment optical density and visual performance in subjects with early age-related macular degeneration.
T he prevalence of age-related macular degeneration (AMD), the leading cause of blind registration in the developed world, 1 is rising because of increasing longevity. 2, 3 Although antivascular endothelial growth factor therapy has resulted in better outcomes for patients with neovascular AMD, 4 this treatment is expensive and cumbersome to the patient and to the health care provider.
Investigators interested in exploring ways of preventing, delaying the onset, or retarding the progression of AMD have directed their attention toward the possible protective role of macular pigment (MP), a yellow-colored pigment that accumulates within the inner retinal layers at the macula 5 and is optically undetectable beyond 7°eccentricity. 6 Macular pigment is composed of three carotenoids, lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ). 7, 8 Macular pigment has generated interest in recent years because of its possible protective role for AMD, putatively attributable to its antioxidant properties and/or its prereceptoral filtration of damaging (short-wavelength) blue light, given that (photo-) oxidative retinal injury is known to be important in the pathogenesis of this condition. 9, 10 Low levels of MP are associated with known risk factors for AMD, namely, increasing age, a positive family history of the condition, tobacco use and obesity, before the onset of disease. 11 Furthermore, observational studies have shown that low levels of carotenoids in the diet [12] [13] [14] [15] [16] and in the serum 13, [17] [18] [19] are associated with the risk of AMD. Importantly, MP augmentation has repeatedly been demonstrated after dietary modification and/or supplementation with its constituent carotenoids, in subjects with and without AMD. [20] [21] [22] [23] [24] [25] [26] Although L and Z concentrations in a variety of foodstuffs have been determined, 27, 28 the MZ composition of foodstuffs typical of a western diet has not been investigated satisfactorily, 28 although it has been identified in certain types of seafood. 29 Interestingly, MZ has been found, albeit in trace amounts, in the serum of subjects who have not been supplemented with this carotenoid. 30 There is consensus that MP plays an important role in visual performance. Many cross-sectional studies have shown a positive association between MP and measures of visual performance, including visual acuity, contrast sensitivity (CS), photostress recovery and glare disability (among others). [31] [32] [33] [34] [35] It has also been shown that supplementation with the macular carotenoids improves parameters of visual function in patients afflicted with the early form of this condition. [36] [37] [38] However, no study has yet investigated the impact of a formulation containing MZ on visual function in subjects with early AMD, or on the natural course of this condition.
Certain properties of MZ render this carotenoid of particular interest when investigating AMD prevention, or when studying the contribution that MP makes to visual performance and experience (in subjects with or without AMD), and these include: MZ is believed to be generated from L in the primate retina 39 ; MZ is the dominant carotenoid at the epicenter of the macula 40 ; MZ seems to be the most powerful antioxidant of the macular carotenoids in the presence of the xanthophyll-binding proteins 41 ; the presence of all three macular carotenoids is required if MP is to maximally exert its antioxidant effects 42 ; the presence of MZ facilitates a wider range of pre-receptoral blue light filtration by MP. 43, 44 Interestingly, an atypical central dip in the spatial profile of MP, characterized by the lack of a central peak with a monotonic decline from the foveal center, is associated with risk for AMD. 45 It is reasonable to hypothesize that such atypical profiles may be attributable, at least in part, to a lack of MZ, and a consequential lack of MP at the site of dominance of this carotenoid (i.e., at the foveal center). Interestingly, supplementation with a formulation containing MZ has the ability, uniquely, to rebuild MP centrally and confer a typical central peak to its spatial profile. 30, 46 This single-blind, randomized control trial was designed to compare the effect of three differing macular carotenoid formulations on MP enhancement, on visual performance, and on disease progression in subjects with early AMD.
Methods

Subjects and Study Design
This study was conducted at the Institute of Vision Research and Institute of Eye Surgery, Waterford, Ireland. The inclusion criteria were: early AMD (the presence of drusen and pigmentary changes) in at least 1 eye; corrected distance visual acuity of $6/12 in the study eye. The exclusion criteria were: a recent history (within 3 months of baseline visit) of macular carotenoid supplementation; diabetes mellitus; any visually consequential ocular comorbidity. Ethics approval was granted by the Waterford Regional Hospital Ethics Committee, and written informed consent was secured from each subject. The research was conducted in accordance with the principles of the Declaration of Helsinki.
The Meso-zeaxanthin Ocular Supplementation Trial: Report 1 (trial registration number: ISRCTN60816411) is a randomized single-blind clinical trial of oral supplementation with 1 of 3 different interventions. Subjects were randomly assigned to one of three supplementation groups, as follows: Group 1: 20 mg L and 2 mg Z (Ultra Lutein AU4 ); Group 2: 10 mg MZ, 10 mg L, and 2 mg Z (Macushield); Group 3: 17 mg MZ, 3 mg L, and 2 mg Z (prepared especially for this trial by Industrial Organica, Monterrey, Mexico). Subjects were required to consume one tablet daily with a meal. Study visits were carried out at baseline and at 12 months. A demographic, medical, ophthalmic, and lifestyle case history was obtained for each patient at baseline.
Macular Pigment Optical Density
Each subject's MP spatial profile was obtained with the Macular Densitometer, using a methodology that has been slightly modified from that developed by Wooten et al. 47 A detailed description of this protocol has been previously described. 48, 49 Visual Performance Corrected distance visual acuity was measured for the study eye monocularly using the Early Treatment Diabetic Retinopathy Study logMAR chart (Test Chart 2000 PRO; Thomson Software Solutions, Hertfordshire, England, United Kingdom), with the room lights on. Contrast sensitivity was also assessed using the logMAR chart at 5 different spatial frequencies (1.2, 2.4, 6.0, 9.6, and 15.15 cycles per degree). For a given spatial frequency, subjects were asked to read out the letters while fixating on the chart at a distance of 6 m. The letter set was randomized during the test at each change of contrast. The percentage contrast of letter optotypes was reduced in 0.15 logCS steps until the lowest contrast value at which subjects see at least 3 letters was reached. The test is then repeated for the other spatial frequencies. Each letter has a nominal logCS value of 0.03. Missed letters at any contrast level are noted. The resultant logCS value for the subject at a particular spatial frequency is calculated by adding any extra letter(s) and/or subtracting missed letters from best logCS value corresponding to the lowest percentage contrast.
Morphologic Assessment
Subjects recruited into the study had early AMD. To establish AMD status, color stereoscopic 30°fundus photographs were obtained using a Zeiss VisuCam (Carl Zeiss Meditec AG, Jena, Germany) and were graded at the Ocular Epidemiology Reading Center at the University of Wisconsin, Madison, WI, using a modified version of the Wisconsin Age-Related Maculopathy Grading System and based on the 11-step AREDS grading scale. 50, 51 For the purposes of this study, a change of two or more steps along the AREDS severity scale was defined as being clinically meaningful. 52 
Clinical Pathology Analysis
Clinical pathology analysis was performed by Biomnis Laboratories (Dublin, Ireland) to test for changes in renal and liver function, lipid profile, hematologic profile, and inflammation markers at baseline and after the 12-month supplementation period. A detailed description of the protocol has been previously described by our group. 53 
Statistical Analysis
Statistical analysis was performed using the software package PASW Statistics 18.0 (IBM Corp, Somers, NY). Power and sample size calculations were obtained using PASS 2008 (NCSS, LLC, Kaysville, UT). A priori statistical methodology was not used in this exploratory study.
Baseline differences between intervention groups were assessed using analysis of variance and contingency table analysis, as appropriate. Baseline and 12-month visit measures, within each treatment group, were compared using the paired-samples t-test; between-group comparisons, using analysis of variance, would have lacked statistical power because of the relatively small sample size in this study. The change in AMD-severity grade between the three intervention groups was assessed using the Pearson chi-square test for contingency tables. The 5% level of significance was used throughout.
For the paired t-test analyses of changes in MP optical density (MPOD) and CS (reported in Tables 3  and 4 ), power calculations were based on a "large" effect size of 0.8 standard deviations (as suggested by Cohen 54 ), and on the smallest of the group sizes (Group 3, n = 14); this study was not powered to detect smaller effect sizes, as per Cohen's definitions. 54 With the usual assumptions (5% level of significance, 2-tailed test), the power is 0.79 for the Group 3 investigations and higher than this for the other two groups. For the contingency table analysis designed to detect changes on the AMDseverity scale (reported in T5 Table 5 ), we also used a "large" effect size (W = 0.5 using Cohen's classification) and, in addition, combined some adjacent columns; in this case, the power is 0.78.
Results
Baseline Analysis
Sixty-seven eyes (of 67 subjects) were recruited into this study. Eight subjects discontinued for personal reasons, 3 were not available to attend for the 12month visit, 2 discontinued for health reasons (deemed to be unrelated to intervention), 1 had cataract surgery on the study eye before the 12-month visit, and 1 patient developed neovascular AMD and did not reattend, leaving 52 subjects with complete data sets for the 12-month analyses: 17 in Group 1, 21 in Group 2, and 14 in Group 3. Baseline demographic, lifestyle, anthropometric, and visual data for the remaining 52 subjects are presented AU5 in T1 Table 1 . Of note, there was no significant difference between the groups in any baseline data variables (including AMD severity, data not presented).
Longitudinal Analysis
Values for MPOD at each eccentricity, at baseline, and 12 months are summarized in T2 Table 2 . Letter CS at baseline and 12 months, for each of the 5 spatial frequencies, is summarized in Table   T3 3. Graphical representations of letter CS at baseline and at 12 months, for the 3 intervention groups, and for each spatial frequency, are displayed in F1 Figure 1 , A-C. The proportion of subjects in each intervention group exhibiting a change in severity scale grade of two or more, considered clinically meaningful for the purpose of this study, 52 was studied. Seventy-nine percent of subjects exhibited no clinically meaningful change in AMD severity grade between baseline and 12 months, with 11% exhibiting deterioration and 10% exhibiting an improvement. There was no statistically significant difference between treatment groups in change in the AMD severity scale (P = 0.455, Pearson chi-square test). The 24-and 36-month data will further inform this important analysis.
Clinical pathology analysis results are reported in Table   T4 4. Of note, 2 variables in Group 1, 2 variables in Group 2, and 2 variables in Group 3 demonstrated statistically significant changes from baseline (in both positive and negative directions). All variables, however, remained within their respective and normal reference ranges.
Discussion
The Meso-zeaxanthin Ocular Supplementation Trial is a randomized single-blind clinical trial that *A subject's weekly intake of carotenoid-rich foods was inputted into an L/Z screener to give a carotenoid-based diet score. Values are weighted for frequency of intake of the food and for bioavailability of L and Z within these foods (the range of scores on the L/Z screener is 0-75).
†Data were not available for 2 subjects. BMI, body mass index; CDVA, corrected distance visual acuity; cpd, cycles per degree; SD, standard deviation.
compares the effect of supplementation with three different macular carotenoid formulations on MPOD, visual performance, and AMD grade, over a period of 12 months, in subjects with early AMD. The MPOD was significantly greater at 1 year than at baseline at all eccentricities for subjects in Groups 2 and 3. Although the observed augmentation in mean MPOD at 12 months did not reach statistical significance for subjects supplemented with high doses of L (Group 1) in the absence of MZ, except at 1.75°eccentricity, it should be noted that the mean increases observed for this group at other eccentricities were not dissimilar in magnitude to those observed for Groups 2 and 3.
The significant rise in MPOD across the spatial profile when all 3 macular carotenoids (Group 2) are included in the formulation, or when supplemented with 17 mg of MZ and small amounts of L and Z (Group 3), and especially the augmentation of MP centrally, is neither surprising nor counter-intuitive, given the known distribution of MP's individual constituent carotenoids. 7 The inclusion of MZ in the formulation is likely to result in augmentation of MP centrally (demonstrated in Groups 2 and 3 here), as this is the site of dominance of this carotenoid. In addition, the inclusion of L in the formulation (as in Groups 1, 2, and 3) will result in MP augmentation at the site of that carotenoid's natural dominance (1.75°), attested to by augmentation of MP at this locus in the high L (but no MZ) group (Group 1). It would seem, therefore, that supplementation with all three macular carotenoids results in the greatest augmentation of MPOD across its spatial profile, thereby putatively affording the greatest protection against AMD. Interestingly, in vitro work has concluded that the antioxidant capacity of the macular carotenoids is maximized when all three macular carotenoids are present. 42 It is unsurprising that there were demonstrable improvements in the CS after augmentation of MP, especially where such augmentation was demonstrated centrally, given the consequential enhancement of prereceptoral filtration of blue light and attenuation of the adverse effects of short-wavelength (blue) light scatter. This is particularly important for subjects with AMD because CS is an important measure of visual function in patients afflicted with the condition. 55 However, the inclusion of MZ in the formulation was required to achieve improvements both at low and high spatial frequencies.
The observation in this study that supplementation with high doses of L (in the absence of MZ) resulted in improved CS at low spatial frequencies only is consistent with the fact that visual function at low spatial frequencies will be mediated by slightly eccentric retinal loci. Of note, concentrations of L are higher in the peripheral macula, compared with the foveola. 56 Previous studies have investigated the impact of macular carotenoid supplementation on CS in subjects with AMD, with most of the studies reporting improvements in the CS after supplementation (with L and Z), 36, 37, [57] [58] [59] although no study to date has tested 60 has shown significant increases in CS at low spatial frequencies after supplementation with either 10 mg L, 20 mg L, or 10 mg L and 10 mg Z (combined), in subjects with early AMD, over a 48-week study period. These findings are in agreement with those reported in this study, which found demonstrable improvements in CS at high spatial frequencies, but only among subjects who were supplemented with a formulation containing MZ, and not among subjects supplementing with high doses of L alone. This study has shown that, from a morphologic perspective, AMD remains stable for at least 12 months after supplementation with the macular carotenoids. However, the findings presented here must be interpreted with full appreciation of the study's principal weaknesses, and these include the small numbers of subjects involved, the study's short duration, and the absence of a placebo group. For the purposes of discussion, it is reasonable to compare our findings with the placebo group in the recently published Carotenoids in Age-Related MAculopathy study, which was a randomized, double-blind, placebo-controlled clinical trial of L (12 mg) and Z (0.6 mg) supplementation with co-antioxidants versus placebo in patients with early AMD. 61 The study population of the Carotenoids in Age-Related MAculopathy study is comparable with that of our study, in inclusion and exclusion criteria, methodology of AMD grading, and demographic and geographic considerations. However, in the Carotenoids in Age-Related MAculopathy study, at 12 months, 47.4% of eyes in the placebo arm (108 of 228 eyes) exhibited an increase of least one grade (progression) along the AMD severity scale (data on file). Interestingly, in this study, only 27% of subjects (all of whom were supplementing with the macular carotenoids) showed progression by one or more steps at 12 months. Of course, a historical comparison such as this one should be interpreted with full appreciation of the fact that the natural course of AMD, particularly over a 12-month period, may not be clinically significant.
No discussion of our findings would be complete without reference to the recently published AREDS2 reports, 62, 63 where analysis of secondary outcomes indicated a benefit of supplementation with L and Z, in terms of AMD progression and preservation of vision, especially in subjects with low dietary intake of those two carotenoids. Given that only two of the three macular carotenoids were used in AREDS2, our findings are rendered all the more clinically meaningful, if not somewhat provocative.
Of note, AREDS, published in 2001, 64 was criticized for non-inclusion of L and Z, and that omission MACULAR CAROTENOIDS AND EARLY AMD SABOUR-PICKETT ET AL prompted AREDS2. Our findings, however, suggest that the exclusion of MZ in AREDS2 represents a potential shortcoming of that study, especially given that MP was measured in less than 2% of AREDS2 patients. Certainly, the opportunity to demonstrate further visual benefit by inclusion of all three of MP's constituent carotenoids was missed, and warrants further study. In this vein, a head-to-head randomized, double-blind, controlled trial of the AREDS2 formula versus the AREDS2 formula fortified with MZ is currently underway. 65 
Conclusion
Macular pigment can be augmented, and CS enhanced, in subjects with early AMD who receive supplemental macular carotenoids. A formulation containing all three macular carotenoids (L, Z, and MZ) may offer advantages over a formulation that does not contain MZ, in terms of improvements in CS and MP augmentation across its spatial profile, the latter putatively affording greater protection against (photo-) oxidative injury. The results of this study *The normative reference ranges for this study were obtained from the insert kits for the instrumentation used by Biomnis Laboratories. Exceptions were the reference ranges for lipids (HDL, LDL, total cholesterol, and triglycerides), which were obtained from the European Guidelines on Cardiovascular Disease Prevention, (69) and for glucose, which were obtained from the World Health Organization (70). AU10 †Total n 6 ¼ 52 because data on pathology analysis was not available for all subjects at both baseline and 12 months. AU11 AAT, alanine aminotransferase; ASA, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HSCP, high sensitive reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume. should inform and prompt a well-designed, controlled clinical trial of supplementation with L, Z, and MZ in subjects with AMD, where outcome measures should include visual function and disease progression. Key words: lutein, zeaxanthin, meso-zeaxanthin, age-related macular degeneration, visual performance.
